SEARCH

SEARCH BY CITATION

References

  • 1
    Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 3847.
  • 2
    Huang LE,Arany Z,Livingston DM,Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem 1996; 271: 322539.
  • 3
    Wang GL,Jiang BH,Rue EA,Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 55104.
  • 4
    Salceda S,Caro J. Hypoxia-inducible factor 1α (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272: 226427.
  • 5
    Huang LE,Gu J,Schau M,Bunn HF. Regulation of hypoxia-inducible factor 1 α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95: 798792.
  • 6
    Kallio PJ,Wilson WJ,O'Brien S,Makino Y,Poellinger L. Regulation of the hypoxia-inducible transcription factor 1 α by the ubiquitin-proteasome pathway. J Biol Chem 1999; 274: 651925.
  • 7
    Ivan M,Kondo K,Yang H,Kim W,Valiando J,Ohh M,Salic A,Asara JM,Lane WS,Kaelin WG,Jr. HIF α targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 4648.
  • 8
    Jaakkola P,Mole DR,Tian YM,Wilson MI,Gielbert J,Gaskell SJ,Kriegsheim Av,Hebestreit HF,Mukherji M,Schofield CJ,Maxwell PH,Pugh CW, et al. Targeting of HIF-1 α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 46872.
  • 9
    Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 72132.
  • 10
    Pastorek J,Pastorekova S,Callebaut I,Mornon JP,Zelnik V,Opavsky R,Zat'ovicova M,Liao S,Portetelle D,Stanbridge EJ,Zavada J,Burny A, et al. Cloning and characterization of MN, a human tumor- associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994; 9: 287788.
  • 11
    Ivanov SV,Kuzmin I,Wei MH,Pack S,Geil L,Johnson BE,Stanbridge EJ,Lerman MI. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998; 95: 12596601.
  • 12
    Zavada J,Zavadova Z,Pastorek J,Biesova Z,Jezek J,Velek J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000; 82: 180813.
  • 13
    Vleugel MM,Greijer AE,Shvarts A,van der Groep P,van Berkel M,Aarbodem Y,van Tinteren H,Harris AL,van Diest PJ,van der Wall E. Differential prognostic impact of hypoxia induced and diffuse HIF-1 α expression in invasive breast cancer. J Clin Pathol 2005; 58: 1727.
  • 14
    Bos R,Zhong H,Hanrahan CF,Mommers EC,Semenza GL,Pinedo HM,Abeloff MD,Simons JW,van Diest PJ,van der Wall E. Levels of hypoxia-inducible factor-1 α during breast carcinogenesis. J Natl Cancer Inst 2001; 93: 30914.
  • 15
    Schindl M,Schoppmann SF,Samonigg H,Hausmaninger H,Kwasny W,Gnant M,Jakesz R,Kubista E,Birner P,Oberhuber G, for Austrian Breast and Colorectal Cancer Study Group. Overexpression of hypoxia-inducible factor 1 α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002; 8: 18317.
  • 16
    Bos R,van der Groep P,Greijer AE,Shvarts A,Meijer S,Pinedo HM,Semenza GL,van Diest PJ,van der Wall E. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003; 97: 157381.
  • 17
    Gruber G,Greiner RH,Hlushchuk R,Aebersold DM,Altermatt HJ,Berclaz G,Djonov V. Hypoxia-inducible factor 1α in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 2004; 6: R191R198.
  • 18
    Chia SK,Wykoff CC,Watson PH,Han C,Leek RD,Pastorek J,Gatter KC,Ratcliffe P,Harris AL. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001; 19: 36608.
  • 19
    Colpaert CG,Vermeulen PB,Fox SB,Harris AL,Dirix LY,Van Marck EA. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat 2003; 81: 13747.
  • 20
    Tomes L,Emberley E,Niu Y,Troup S,Pastorek J,Strange K,Harris A,Watson PH. Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 2003; 81: 619.
  • 21
    Span PN,Bussink J,Manders P,Beex LV,Sweep CG. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 2003; 89: 2716.
  • 22
    Cayre A,Rossignol F,Clottes E,Penault-Llorca F. aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer. Breast Cancer Res 2003; 5: R223R230.
  • 23
    Dales JP,Garcia S,Meunier-Carpentier S,Andrac-Meyer L,Haddad O,Lavaut MN,Allasia C,Bonnier P,Charpin C. Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005; 116: 7349.
  • 24
    Kronblad A,Jirstrom K,Ryden L,Nordenskjold B,Landberg G. Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer 2006; 118: 260916.
  • 25
    Berra E,Benizri E,Ginouvès A,Volmat V,Roux D,Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 2003; 22: 408290.
  • 26
    Richard DE,Berra E,Gothié E,Roux D,Pouysségur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999; 274: 326317.
  • 27
    Stroka DM,Burkhardt T,Desbaillets I,Wenger RH,Neil DA,Bauer C,Gassmann M,Candinas D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 2001; 15: 244553.
  • 28
    Brown JM,Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 43747.
  • 29
    Wiesener MS,Munchenhagen PM,Berger I,Morgan NV,Roigas J,Schwiertz A,Jurgensen JS,Gruber G,Maxwell PH,Loning SA,Frei U,Maher ER, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas. Cancer Res 2001; 61: 521522.
  • 30
    Wykoff CC,Beasley NJ,Watson PH,Turner KJ,Pastorek J,Sibtain A,Wilson GD,Turley H,Talks KL,Maxwell PH,Pugh CW,Ratcliffe PJ, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 707583.
  • 31
    Kurebayashi J,Otsuki T,Moriya T,Sonoo H. Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 2001; 92: 1093101.